156 related articles for article (PubMed ID: 19925028)
1. Three assays show differences in binding of wild-type and mutant p53 to unique gene sequences.
Chandrachud U; Gal S
Technol Cancer Res Treat; 2009 Dec; 8(6):445-53. PubMed ID: 19925028
[TBL] [Abstract][Full Text] [Related]
2. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.
Park DJ; Nakamura H; Chumakov AM; Said JW; Miller CW; Chen DL; Koeffler HP
Oncogene; 1994 Jul; 9(7):1899-906. PubMed ID: 8208536
[TBL] [Abstract][Full Text] [Related]
3. TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation.
Malaguarnera R; Vella V; Pandini G; Sanfilippo M; Pezzino V; Vigneri R; Frasca F
Mol Cancer Res; 2008 Jan; 6(1):64-77. PubMed ID: 18234963
[TBL] [Abstract][Full Text] [Related]
4. Scintillation proximity assay for DNA binding by human p53.
Gal S; Cook JR; Howells L
Biotechniques; 2006 Sep; 41(3):303-8. PubMed ID: 16989090
[TBL] [Abstract][Full Text] [Related]
5. PRIMA-1 selectively induces global DNA demethylation in p53 mutant-type thyroid cancer cells.
Qiang W; Jin T; Yang Q; Liu W; Liu S; Ji M; He N; Chen C; Shi B; Hou P
J Biomed Nanotechnol; 2014 Jul; 10(7):1249-58. PubMed ID: 24804545
[TBL] [Abstract][Full Text] [Related]
6. Rescue of mutant p53 transcription function by ellipticine.
Peng Y; Li C; Chen L; Sebti S; Chen J
Oncogene; 2003 Jul; 22(29):4478-87. PubMed ID: 12881704
[TBL] [Abstract][Full Text] [Related]
7. p21/CDKN1A mediates negative regulation of transcription by p53.
Löhr K; Möritz C; Contente A; Dobbelstein M
J Biol Chem; 2003 Aug; 278(35):32507-16. PubMed ID: 12748190
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.
O'Connor PM; Jackman J; Bae I; Myers TG; Fan S; Mutoh M; Scudiero DA; Monks A; Sausville EA; Weinstein JN; Friend S; Fornace AJ; Kohn KW
Cancer Res; 1997 Oct; 57(19):4285-300. PubMed ID: 9331090
[TBL] [Abstract][Full Text] [Related]
9. Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination.
Nakamura S; Roth JA; Mukhopadhyay T
Mol Cell Biol; 2000 Dec; 20(24):9391-8. PubMed ID: 11094089
[TBL] [Abstract][Full Text] [Related]
10. Reexpression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53.
Fagin JA; Tang SH; Zeki K; Di Lauro R; Fusco A; Gonsky R
Cancer Res; 1996 Feb; 56(4):765-71. PubMed ID: 8631011
[TBL] [Abstract][Full Text] [Related]
11. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
12. Tumor-derived mutations within the DNA-binding domain of p53 that phenotypically resemble the deletion of the proline-rich domain.
Roth J; Koch P; Contente A; Dobbelstein M
Oncogene; 2000 Mar; 19(14):1834-42. PubMed ID: 10777217
[TBL] [Abstract][Full Text] [Related]
13. The p53 tumor suppressor gene and gene product.
Levine AJ
Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
[TBL] [Abstract][Full Text] [Related]
14. Identification of p53 sequence elements that are required for MDM2-mediated nuclear export.
Gu J; Nie L; Wiederschain D; Yuan ZM
Mol Cell Biol; 2001 Dec; 21(24):8533-46. PubMed ID: 11713288
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
16. Target gene modulation in hepatocellular carcinomas by decreased DNA-binding of p53 mutations.
Kubicka S; Trautwein C; Niehof M; Manns M
Hepatology; 1997 Apr; 25(4):867-73. PubMed ID: 9096590
[TBL] [Abstract][Full Text] [Related]
17. Aberrant p53 protein expression and function in a panel of hematopoietic cell lines with different p53 mutations.
Kamihira S; Terada C; Sasaki D; Yanagihara K; Tsukasaki K; Hasegawa H; Yamada Y
Eur J Haematol; 2009 Apr; 82(4):301-7. PubMed ID: 19220422
[TBL] [Abstract][Full Text] [Related]
18. Alterations in gene expression and sensitivity to genotoxic stress following HdmX or Hdm2 knockdown in human tumor cells harboring wild-type p53.
Heminger K; Markey M; Mpagi M; Berberich SJ
Aging (Albany NY); 2009 Jan; 1(1):89-108. PubMed ID: 19946469
[TBL] [Abstract][Full Text] [Related]
19. p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3.
Lin J; Tang H; Jin X; Jia G; Hsieh JT
Oncogene; 2002 May; 21(19):3082-8. PubMed ID: 12082540
[TBL] [Abstract][Full Text] [Related]
20. The DNA binding and accumulation of p53 from breast cancer cell lines and the link with serine 15 phosphorylation.
Ray D; Murphy KR; Gal S
Cancer Biol Ther; 2012 Aug; 13(10):848-57. PubMed ID: 22785213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
